Takeda makes Orzeyful, the first orexin agonist for narcolepsy type 1, available in the United States
+1 new source since this summary was written
Takeda Pharmaceutical announced that Orzeyful (oveporexton) can now be prescribed to adult patients with narcolepsy type 1 in the U.S. The drug received FDA approval in August 2026 and will be shipped through Accredo Specialty Pharmacy. Phase‑3 trials reported insomnia in 60% of the 2 mg twice‑daily group and 55% of the 1 mg twice‑daily group, and urinary frequency in 58% and 53% respectively, versus 1% and 5% for placebo. Takeda also noted that the medication is a schedule IV controlled substance and is not recommended for patients on strong CYP3A inhibitors or with severe hepatic or renal impairment.
Why it matters
The launch introduces the first approved orexin‑receptor agonist for this disorder, expanding treatment options for an estimated 120,000 U.S. patients. Takeda’s share price rose 2.35% in pre‑market trading, reflecting investor optimism about the new product’s revenue potential.
Key facts
- 1Orzeyful became available by prescription in the United States for adult narcolepsy type 1 patients. investing.com
- 2The FDA approved the drug in August 2026. investing.com
- 3Insomnia was reported in 60% of patients taking 2 mg twice daily and 55% of those taking 1 mg twice daily, compared with 1% on placebo. investing.com
- 4Urinary frequency occurred in 58% and 53% of the respective dosage groups, versus 5% for placebo. investing.com
- 5Takeda will distribute the medication through Accredo Specialty Pharmacy. investing.com
- 6TAK stock was up 2.35% in pre‑market trading at $21.35. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.